Anti-myeloma pro-apoptotic Pt(II) diiodido complexes
Sign Up to like & getrecommendations! Published in 2023 at "Inorganic Chemistry Frontiers"
DOI: 10.1039/d3qi00327b
Abstract: Platinum-based agents unwaveringly hold their prominent position in cancer treatment. Current research emphasizes finding novel complexes for hard-to-treat cancers with minimum side effects, capable of overcoming resistance. This work presents... read more here.
Keywords: myeloma pro; pro apoptotic; anti myeloma; apoptotic diiodido ... See more keywords
Venetoclax: the first anti‐myeloma agent with a reliable biomarker
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16493
Abstract: Multiple myeloma (MM) is still considered an incurable disease by the majority of experts in the field. Thus, new drugs with novel mechanisms of action are needed. Besides the next generations of proteasome inhibitors (PIs)… read more here.
Keywords: mcl; venetoclax; myeloma; bcl ... See more keywords
The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-21-0119
Abstract: P8-D6 is a novel dual inhibitor of human topoisomerase I (TOP1) and II (TOP2) with broad pro-apoptotic antitumor activity. NCI-60 screening revealed markedly improved cytotoxicity of P8-D6 against solid and leukemia cell lines compared with… read more here.
Keywords: topoisomerase; myeloma; novel dual; dual topoisomerase ... See more keywords
A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115922
Abstract: Introduction: Rationale for anticancer vaccine therapy is based on humoral and/or cellular response against unique tumor antigens (Ag). Peptide vaccines specific for Ag are under investigation for patients with multiple myeloma (MM). Among cell-based vaccines,… read more here.
Keywords: phase; response; therapy; vaccine ... See more keywords
Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26831
Abstract: Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission. Thus, identification of new therapeutic agents that simultaneously suppress MM growth and protect bone… read more here.
Keywords: myeloma; potent anti; anti resorptive; bone ... See more keywords
Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.00531
Abstract: Because of the essential role of signal transducer and activator of transcription 3 (STAT3) in proliferation, anti-apoptosis, and chemoresistance of multiple myeloma (MM), we investigated whether icariin, a prenylated flavonol glycoside, inhibits both constitutive and… read more here.
Keywords: icariin; myeloma; stat3; myeloma effects ... See more keywords
SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.841308
Abstract: Multiple myeloma (MM) is a plasma cell malignancy that remains incurable. The protein tyrosine phosphatase SHP2 is a central node regulating RAS/mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) signaling pathway which plays a crucial… read more here.
Keywords: myeloma; shp2 inhibitors; activity; shp2 ... See more keywords